Alexander Kroemer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Kroemer has a total of 184 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Ruf
Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
21 shared publications - Bernd Heinrich
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany
21 shared publications Chi Ma
21 shared publications- Simon Wabitsch
Gastrointestinal Malignancy Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
21 shared publications - Tim F. Greten
Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, USA
21 shared publications Varun Subramanyam
21 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70425
Living Donor Liver Transplantation in Pediatric Situs Inversus: A Case Series and Systematic Review
Liver transplantation (LT) in patients with situs inversus (S‐I) is rare and technically challenging. The literature on such cases, particularly in pediatric populations, remains limited. Here, we report the surgical considerations and outcomes of two pediatric recipients with situs inversus abdominalis who underwent liver transplantation for biliary atresia (BA). We conducted a retrospective descriptive analysis of two pediatric patients with S‐I who underwent LT for BA. Pretransplant imaging, intraoperative details, and posttransplant outcomes were evaluated. Additionally, we performed a systematic review of the literature on LT in patients with S‐I. We describe the successful living donor liver transplantation (LDLT) of two pediatric patients with S‐I abdominalis and BA, each presenting with complex anatomical variations, including polysplenia, intestinal malrotation, and vascular anomalies such as absence of the inferior vena cava (IVC). Both patients underwent technically demanding procedures requiring customized vascular and biliary reconstructions, along with definitive correction of intestinal malrotation to restore anatomical intestinal orientation. Both patients had an uncomplicated immediate postoperative course. During follow‐up, one patient developed a diaphragmatic hernia that required surgical repair. Our systematic review confirms that, although rare, pediatric LT in patients with S‐I is increasingly reported with favorable outcomes. These findings support the feasibility and safety of LT in children with S‐I when guided by meticulous preoperative planning and intraoperative adaptability. Liver transplantation in pediatric patients with S‐I is feasible and can be performed safely with careful preoperative planning and tailored surgical techniques. Our experience, together with the available literature, supports the inclusion of these patients as suitable candidates for transplantation despite their complex anatomy.
- 7 August 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (8) , e70425
Open AccessLiving Donor Liver Transplantation in Pediatric Situs Inversus: A Case Series and Systematic Review
Liver transplantation (LT) in patients with situs inversus (S‐I) is rare and technically challenging. The literature on such cases, particularly in pediatric populations, remains limited. Here, we report the surgical considerations and outcomes of two pediatric recipients with situs inversus abdominalis who underwent liver transplantation for biliary atresia (BA). We conducted a retrospective descriptive analysis of two pediatric patients with S‐I who underwent LT for BA. Pretransplant imaging, intraoperative details, and posttransplant outcomes were evaluated. Additionally, we performed a systematic review of the literature on LT in patients with S‐I. We describe the successful living donor liver transplantation (LDLT) of two pediatric patients with S‐I abdominalis and BA, each presenting with complex anatomical variations, including polysplenia, intestinal malrotation, and vascular anomalies such as absence of the inferior vena cava (IVC). Both patients underwent technically demanding procedures requiring customized vascular and biliary reconstructions, along with definitive correction of intestinal malrotation to restore anatomical intestinal orientation. Both patients had an uncomplicated immediate postoperative course. During follow‐up, one patient developed a diaphragmatic hernia that required surgical repair. Our systematic review confirms that, although rare, pediatric LT in patients with S‐I is increasingly reported with favorable outcomes. These findings support the feasibility and safety of LT in children with S‐I when guided by meticulous preoperative planning and intraoperative adaptability. Liver transplantation in pediatric patients with S‐I is feasible and can be performed safely with careful preoperative planning and tailored surgical techniques. Our experience, together with the available literature, supports the inclusion of these patients as suitable candidates for transplantation despite their complex anatomy.
- 24 April 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1678-1679
Beyond Histology: A Single-cell Perspective on Intestinal Transplantation
- 24 April 2025
- Published by Wolters Kluwer Health in Transplantation
- Vol. 109 (11) , 1678-1679
Beyond Histology: A Single-cell Perspective on Intestinal Transplantation
- Open Access
- 28 November 2024
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 35
Severe hepatopulmonary syndrome with end-stage liver cirrhosis associated with pan-hypopituitarism in a pediatric patient
- 28 November 2024
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 35
Open AccessSevere hepatopulmonary syndrome with end-stage liver cirrhosis associated with pan-hypopituitarism in a pediatric patient
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the fastest growing cancer worldwide in part due to the obesity epidemic and fatty liver disease, particularly nonalcoholic steatohepatitis (NASH). Chronic inflammation with the release of cytokines and chemokines with activation of hepatic stellate cells results in changes of the liver extracellular matrix (ECM) that predisposes to the development of HCC. Blood levels of the gastrointestinal peptide cholecystokinin (CCK) are increased in humans and mice consuming a high-fat diet. We found that the CCK-B receptor (CCK-BR) expression increased in the livers of mice with NASH. Treatment of mice with a CCK-BR antagonist, proglumide, prevented NASH, lowered hepatic inflammatory cytokines and chemokines, reduced oxidative stress, decreased F4/80+ hepatic macrophages, and prevented HCC. CCK-AR and CCK-BR expression was increased in both murine and human HCC cell lines compared with that of normal liver, and CCK stimulated the growth of wild-type and CCK-A receptor knockout HCC cells in vitro, but not CCK-BR knockout cells suggesting that the CCK-BR mediates proliferation. Proglumide therapy significantly reduced growth by 70% and 73% in mice bearing Dt81Hepa1–6 or in RIL-75 HCC tumors, respectively. IHC of a human liver tissue array with a selective CCK-BR antibody revealed staining of human HCC and no staining in normal liver.Prevention Relevance:This investigation demonstrates the role of the gastrointestinal peptide cholecystokinin (CCK) in hepatocellular carcinoma (HCC) and how CCK-BR blockade reverses the premalignant state of the hepatic extracellular matrix hence, rendering it less susceptible to the development of HCC. Thereby, CCK-BR blockade is a novel approach for the prevention/treatment of HCC.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the fastest growing cancer worldwide in part due to the obesity epidemic and fatty liver disease, particularly nonalcoholic steatohepatitis (NASH). Chronic inflammation with the release of cytokines and chemokines with activation of hepatic stellate cells results in changes of the liver extracellular matrix (ECM) that predisposes to the development of HCC. Blood levels of the gastrointestinal peptide cholecystokinin (CCK) are increased in humans and mice consuming a high-fat diet. We found that the CCK-B receptor (CCK-BR) expression increased in the livers of mice with NASH. Treatment of mice with a CCK-BR antagonist, proglumide, prevented NASH, lowered hepatic inflammatory cytokines and chemokines, reduced oxidative stress, decreased F4/80+ hepatic macrophages, and prevented HCC. CCK-AR and CCK-BR expression was increased in both murine and human HCC cell lines compared with that of normal liver, and CCK stimulated the growth of wild-type and CCK-A receptor knockout HCC cells in vitro, but not CCK-BR knockout cells suggesting that the CCK-BR mediates proliferation. Proglumide therapy significantly reduced growth by 70% and 73% in mice bearing Dt81Hepa1–6 or in RIL-75 HCC tumors, respectively. IHC of a human liver tissue array with a selective CCK-BR antibody revealed staining of human HCC and no staining in normal liver.Prevention Relevance:This investigation demonstrates the role of the gastrointestinal peptide cholecystokinin (CCK) in hepatocellular carcinoma (HCC) and how CCK-BR blockade reverses the premalignant state of the hepatic extracellular matrix hence, rendering it less susceptible to the development of HCC. Thereby, CCK-BR blockade is a novel approach for the prevention/treatment of HCC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the fastest growing cancer worldwide in part due to the obesity epidemic and fatty liver disease, particularly nonalcoholic steatohepatitis (NASH). Chronic inflammation with the release of cytokines and chemokines with activation of hepatic stellate cells results in changes of the liver extracellular matrix (ECM) that predisposes to the development of HCC. Blood levels of the gastrointestinal peptide cholecystokinin (CCK) are increased in humans and mice consuming a high-fat diet. We found that the CCK-B receptor (CCK-BR) expression increased in the livers of mice with NASH. Treatment of mice with a CCK-BR antagonist, proglumide, prevented NASH, lowered hepatic inflammatory cytokines and chemokines, reduced oxidative stress, decreased F4/80+ hepatic macrophages, and prevented HCC. CCK-AR and CCK-BR expression was increased in both murine and human HCC cell lines compared with that of normal liver, and CCK stimulated the growth of wild-type and CCK-A receptor knockout HCC cells in vitro, but not CCK-BR knockout cells suggesting that the CCK-BR mediates proliferation. Proglumide therapy significantly reduced growth by 70% and 73% in mice bearing Dt81Hepa1–6 or in RIL-75 HCC tumors, respectively. IHC of a human liver tissue array with a selective CCK-BR antibody revealed staining of human HCC and no staining in normal liver.Prevention Relevance:This investigation demonstrates the role of the gastrointestinal peptide cholecystokinin (CCK) in hepatocellular carcinoma (HCC) and how CCK-BR blockade reverses the premalignant state of the hepatic extracellular matrix hence, rendering it less susceptible to the development of HCC. Thereby, CCK-BR blockade is a novel approach for the prevention/treatment of HCC.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the fastest growing cancer worldwide in part due to the obesity epidemic and fatty liver disease, particularly nonalcoholic steatohepatitis (NASH). Chronic inflammation with the release of cytokines and chemokines with activation of hepatic stellate cells results in changes of the liver extracellular matrix (ECM) that predisposes to the development of HCC. Blood levels of the gastrointestinal peptide cholecystokinin (CCK) are increased in humans and mice consuming a high-fat diet. We found that the CCK-B receptor (CCK-BR) expression increased in the livers of mice with NASH. Treatment of mice with a CCK-BR antagonist, proglumide, prevented NASH, lowered hepatic inflammatory cytokines and chemokines, reduced oxidative stress, decreased F4/80+ hepatic macrophages, and prevented HCC. CCK-AR and CCK-BR expression was increased in both murine and human HCC cell lines compared with that of normal liver, and CCK stimulated the growth of wild-type and CCK-A receptor knockout HCC cells in vitro, but not CCK-BR knockout cells suggesting that the CCK-BR mediates proliferation. Proglumide therapy significantly reduced growth by 70% and 73% in mice bearing Dt81Hepa1–6 or in RIL-75 HCC tumors, respectively. IHC of a human liver tissue array with a selective CCK-BR antibody revealed staining of human HCC and no staining in normal liver.Prevention Relevance:This investigation demonstrates the role of the gastrointestinal peptide cholecystokinin (CCK) in hepatocellular carcinoma (HCC) and how CCK-BR blockade reverses the premalignant state of the hepatic extracellular matrix hence, rendering it less susceptible to the development of HCC. Thereby, CCK-BR blockade is a novel approach for the prevention/treatment of HCC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Supplemental Table S1 and Supplemental Figures S1-S3
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer
Supplemental Table S1 and Supplemental Figures S1-S3
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Predicted risk group (BRBarray)_LMedits
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Predicted risk group (BRBarray)_LMedits